Ultragenyx EVP granted RSUs and stock options
Ultragenyx Pharmaceutical EVP & Chief Commercial Officer Erik Harris received new equity awards.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Ultragenyx Pharmaceutical EVP & Chief Commercial Officer Erik Harris received new equity awards. He was granted 28,895 shares of common stock in the form of restricted stock units (RSUs) under the company’s 2023 Incentive Plan, bringing his direct common stock holdings to 118,410 shares.
He also received a stock option for 49,960 shares of common stock at an exercise price of $24.52 per share, expiring on April 16, 2036. The RSUs vest in four equal annual installments, while the option vests 25% on the first anniversary of the grant date and 1/48 monthly thereafter.
Insider Trade Summary
Grant/Award: 78,855 shares
Grant/Award
2 txns
Insider
Harris Erik
Role
EVP & Chief Commercial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 49,960 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 28,895 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 49,960 contracts (Direct);
Common Stock — 118,410 shares (Direct)
Footnotes (3)
- F1. Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
- F2. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- F3. On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
Key Figures
RSU grant size: 28,895 shares
Post-grant common stock holdings: 118,410 shares
Stock option grant size: 49,960 shares
+4 more
7 metrics
RSU grant size
28,895 shares
Restricted Stock Units granted April 16 under 2023 Incentive Plan
Post-grant common stock holdings
118,410 shares
Direct common stock held after RSU award
Stock option grant size
49,960 shares
New stock option covering common stock
Option exercise price
$24.52 per share
Conversion or exercise price for 49,960-share option
Option expiration
April 16, 2036
Expiration date of the granted stock option
RSU vesting schedule
25% annually over 4 years
RSUs vest 1/4 on each grant anniversary
Option vesting schedule
25% at 1 year, then 1/48 monthly
From option anniversary date until fully vested
Key Terms
Restricted Stock Units ("RSUs"), 2023 Incentive Plan, Stock Option (Right to Buy), Option Anniversary Date, +1 more
5 terms
Restricted Stock Units ("RSUs") financial
"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2023 Incentive Plan financial
"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with underlying security title Common Stock."
Option Anniversary Date financial
"On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest;"
vesting conditions financial
"shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."
Vesting conditions are the rules that determine when someone earning company stock or stock options actually gains the right to keep or sell them, typically based on staying with the company for a set time or meeting performance targets. Think of it like keys that unlock gradually — some unlock by calendar date, others only after agreed milestones. Investors care because vesting shapes management incentives, the timing of share sales, and the number of shares that can enter the market, which can affect a company's valuation and ownership mix.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did Ultragenyx (RARE) EVP Erik Harris receive?
Erik Harris received 28,895 restricted stock units and a stock option for 49,960 shares. The option has a $24.52 exercise price and expires in 2036, representing compensation-based equity rather than an open-market stock purchase or sale.
How do Erik Harris’s new RSUs at Ultragenyx (RARE) vest?
The 28,895 RSUs vest in four equal annual installments. One-quarter of the underlying shares vests on each anniversary of the April 16 grant date, so the award becomes fully vested on the fourth anniversary, subject to the plan’s conditions.
What are the terms of Erik Harris’s new Ultragenyx (RARE) stock option?
The stock option covers 49,960 shares of common stock at a $24.52 exercise price. Twenty-five percent of the shares vest one year after grant, and 1/48 of the original amount vests each month thereafter until the April 16, 2036 expiration.
Are Erik Harris’s Ultragenyx (RARE) transactions open-market buys or compensation?
These transactions are compensation-related awards, not open-market trades. Both the 28,895 RSUs and the 49,960-share stock option were granted under Ultragenyx’s 2023 Incentive Plan, with no purchase price paid for the awards at grant.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates